title: Validation of targets and drug candidates in an engineered three-dimensional cardiac tissue model.
abstract: High-throughput target discovery confronts the biopharmaceutical industry with a plethora of target candidates. The validation of these candidates in disease-specific animal models often lacks the required throughput. Here, we discuss perspectives and limitations of a novel engineered three-dimensional cardiac tissue, which enables the influence of gene and drug intervention to be monitored on a cellular and molecular level under physiological conditions in sufficient throughput. The model is an extremely helpful filter to prioritize multiple development candidates before moving a project into large animal models with higher predictivity.
authors.affiliation: Department of Research, MediGene AG, Lochhamer Str. 11, 82152 Martinsried, Germany.
authors.forename: Barbara T
authors.initials: BT
authors.lastname: Navé
authors.forename: Michael
authors.initials: M
authors.lastname: Becker
authors.forename: Volker
authors.initials: V
authors.lastname: Roenicke
authors.forename: Thomas
authors.initials: T
authors.lastname: Henkel
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006321:Heart / Q000033:anatomy & histology* / Q000187:drug effects*; D006801:Humans; D008953:Models, Anatomic; D009206:Myocardium / Q000166:cytology; D015203:Reproducibility of Results
chemical_list: D002317:Cardiovascular Agents